Biomarkers Consortium General Intellectual Property and Data Sharing Principles
|
|
- Harold Webster
- 6 years ago
- Views:
Transcription
1 Biomarkers Consortium General Intellectual Property and Data Sharing Principles I. Introduction The goals of the Biomarkers Consortium are to: 1. promote the discovery, development, qualification, and regulatory acceptance of biomarkers; 2. make research results and data arising under a Project Team ( PT ) activity broadly available, subject to agreed upon data sharing plans; and 3. to help speed disease-specific research. Biomarkers Consortium activities support the expeditious development of biomarkers to ensure that safe, innovative, and effective new medicines and diagnostics are developed to address healthcare needs, improve medical care, and promote and improve public health. The intent of this document is to outline general principles relating to Intellectual Property and Data sharing aspects of the Biomarkers Consortium. The purpose of these principles is to facilitate the use of data and technologies in expanded biomarker research and development efforts conducted by the Biomarkers Consortium while ensuring adequate incentives to commercialize biomarker technologies, and while ensuring compliance with relevant requirements of antitrust law. All Participants agree to implement the Intellectual Property and Data Sharing Principles of the Biomarkers Consortium. In the context of individual projects, Participants agree to explore all mechanisms available, consistent with their individual missions and the interests of the public health, to do so most effectively. 1 The principles address the following issues: The advance planning and approval of specific projects; 1 It is understood that existing Federal statutes, regulations and established policies will govern the conduct of any Federal Participant in the Biomarkers Consortium.
2 The management of pre-existing Data and other Intellectual Property, including, for example, confidential research Data or patented inventions shared by members for specific Biomarkers Consortium projects; and The management of new Data and Intellectual Property arising from Biomarkers Consortium-sponsored projects. The principles apply to all activities of the Biomarkers Consortium as carried out by both Biomarkers Consortium members and Project Team Participants, subject to any applicable Federal statutory or regulatory requirements or policies. II. Definition of Key Terms Biomarkers Consortium or Consortium refers to a public-private scientific partnership between the Foundation for the National Institutes of Health ( FNIH ), the National Institutes of Health ( NIH ), the Food and Drug Administration ( FDA ), the Centers for Medicare & Medicaid Services ( CMS ), members of the pharmaceutical, biotechnology, diagnostics, and medical device industries, members of non-profit organizations, and academicians. Biomarkers Consortium Antitrust Policy and Guidelines are set forth in a separate document. Project Team ( PT ) refers to a group of individuals or entities created by the Biomarkers Consortium to plan and execute a particular scientific project. Participants in each PT ( PT Participants ) shall be listed in a roster of PT Participants which shall define the membership of each PT, to be maintained and updated by FNIH. PT Participants may be drawn from any segment of the Federal agencies or public or private entities that form the Biomarkers Consortium, or may be otherwise appointed by the Executive Committee or Steering Committee from academia, advocacy, or other organizations, provided that they are making substantial contributions, financial or otherwise, in the project. Data refers to information relating to characteristics and observations of a scientific or technical nature including information and results arising from scientific experiments, regardless of form or the media on which they may be recorded. The term includes raw data, derived data, proprietary data, technical data and compilations of data. For the purposes of this definition, the term does not include data incidental to the administration of Biomarkers Consortium projects, such as financial, administrative, cost and pricing, or management information. Participant refers to any party paying annual dues to the Biomarkers Consortium ( Contributing Members ), companies that contribute to Biomarkers Consortium projects, and other individuals representing academia, advocacy, industry or other organizations that make substantial contributions, financial or otherwise, to Biomarkers Consortium activities and who appear on membership rosters. 2
3 Federal Participant refers to the National Institutes of Health ( NIH ), the Food and Drug Administration ( FDA ), the Centers for Medicare & Medicaid Services ( CMS ) or any other entity of the federal government, and to any employee or representative of such an entity, that is a Participant in the Biomarkers Consortium or otherwise involved in the Biomarkers Consortium s activities. Non-Federal Participant refers to any Participant that is not a Federal Participant of the Biomarkers Consortium. Third Party refers to an individual or entity that is not a Participant or otherwise involved in the Biomarkers Consortium. Invention refers to any subject matter and discovery patentable or otherwise protectable under Title 35 of the United States Code. Biomarkers Consortium Inventions are Inventions conceived or first reduced to practice in the conduct of a Biomarkers Consortium project. Intellectual Property refers to patents, patent applications, know-how, trade secrets, copyrights, and computer programs. III. Project Plans and Approval No Project Plan will be initiated or implemented prior to EC authorization. The EC and SC concept review and approval process is outlined in the document Two-Phased Project Approval Process: Concept Clearance and Project Plan Review. Each Project Plan submitted to the Biomarkers Consortium EC shall, at minimum, address the following issues: Setting project objectives. Identifying the information, materials, methods, Intellectual Property rights and regulatory or governmental approvals necessary to achieve the project objectives; identifying any impediments to achieve the project objectives, including but not limited to licenses, confidentiality agreements, contract obligations, limitations related to consent (Data, materials, or sample use), or other legal or contractual barriers to achieving project goals; and evaluating the likelihood of achieving the project objectives. This should include identifying relevant pre-existing Data, which should be limited and sufficient to achieve the goals of the project. Establishing clear rules for the triggers, timing, and scope for PT Participants to disclose to the SC or other appropriate Biomarkers Consortium Committee any patents or patent applications that the PT Participants control that relate to the project objectives, whether pre-existing, arising during the course of the project, or arising out of the activities of the Biomarkers Consortium. 3
4 o In general, each PT Participant shall disclose to the SC or appropriate Biomarkers Consortium Committee the existence of any patents or patent applications owned by the Participant, controlled by the Participant, or licensed by the Participant with authority to disclose, that: (i) refer to or rely upon any Data to be shared in the project; or (ii) whose use or practice is reasonably likely to be required to accomplish the objectives of the project or use the results of the project,. The disclosures will include the identity of such patents or patent applications relevant to the project as soon as they become material to the discussion, but in no case later than the submission of the project plan to the EC. o Any new Participant prior to joining a PT shall agree to conform to the aforementioned principles. o All disclosures should identify and summarize the relevant substance of the patent or patent application and how it relates to the specific project objective(s). Confidential information will be kept confidential consistent with the Biomarkers Consortium Addendum to the Foundation for NIH s Confidentiality Policy. Establishing clear rules for the ownership and/or licensing of any Data and Intellectual Property arising from the Biomarkers Consortium project or disclosed by Biomarkers Consortium members as relating to the project objectives. Such rules should be embodied in a binding agreement among PT Participants and must be reviewed by FNIH counsel for antitrust compliance prior to final acceptance by the parties. Project Plans shall address any restrictions that apply to the use of pre-existing Data. For projects where pre-existing data from multiple sources will be used, PT Participants, in consultation with FNIH antitrust counsel, will aggregate preexisting data to the extent necessary to comply with antitrust guidelines. Such data will then be analyzed in the aggregated form and should be anonymized for company/institution source. o Demonstrating how Participants in the PT will comply with all applicable human subjects research and other privacy laws and regulations. Defining a plan for use and analysis of pre-existing Data and Data generated in the course of the project. Establishing rules and conditions for addressing confidentiality, Data access, Intellectual Property, and rights in Data for any funding recipients utilized in the conduct of the PT project. Establishing a comprehensive Data access plan defining which data arising from the project will be made publicly available, when, and how; a publication plan if appropriate; and scope, mechanisms and methods of Data access. The Data 4
5 access plan shall include, but need not be limited to, provisions regarding the following factors: (1) timing of any public Data release; (2) protection of Data that raises privacy concerns; (3) protection of confidential or proprietary Data that have been pooled in order to complete the required analysis or have been generated in the analysis; (4) appropriate handling of Data that may become part of a regulatory submission; and (5) address use of data by individual Participants, for example whether Participants analysis of Data falls within the scope of project plan. Establishing a comprehensive plan to manage and distribute materials and samples generated in the course of the project. Identifying a roster of the PT Participants, to be updated as necessary. Defining project scope and term, including beginning and ending milestones. IV. Pre-Existing Data and Intellectual Property The PT s activities will require the use of pre-existing Data and Intellectual Property, including, for example, confidential research data or inventions shared by PT Participants for specific projects. The following guidelines will govern the sharing of pre-existing Data and Intellectual Property with PT Participants. As a condition of continued participation in a project, all PT Participants will adhere to the rules established under the project plan and approved by the EC for disclosure of patents, patent applications, or other Intellectual Property. Non-Federal Participants in a PT will grant all other Participants of that PT a limited, non-exclusive, royalty-free and remuneration-free license to use each Participant s relevant pre-existing Data and Intellectual Property for research purposes only in connection with the project. Any other licenses necessary for the project must be agreed upon by the Participants in the PT before the project commences. Each Federal Participant in a PT will grant all other Participants of the PT access on a non-exclusive, royalty-free, and remuneration-free basis, to its pre-existing Data, materials, and know how for research purposes in connection with the project. In addition, Federal Participants in a PT will seriously consider requests from all other Participants in the PT for licenses to inventions under 37 C.F.R. Part 404, including remuneration free research use licenses limited to the scope of Biomarkers Consortium project. The PT will seek to obtain limited, non-exclusive licenses from Third Parties to use pre-existing Data and Intellectual Property if determined necessary, preferably on royalty and remuneration-free terms, for research purposes only in connection with the project. 5
6 The Biomarkers Consortium, its members, and the pertinent PT Participants will not gain any ownership rights to pre-existing Data and Intellectual Property of any other party as a result of participating in Biomarkers Consortium activities. PT Participants will have the right to analyze pre-existing Data within the scope of the project and data analysis plan using their own methodologies with the express condition that they will disclose methods and results arising out of their analysis to the PT within a reasonable time to be agreed by the PT. The status of any inventions from such activity should be covered or considered in the projectspecific Intellectual Property plan. V. New Data and Biomarkers Consortium Inventions The Biomarkers Consortium s activities are also expected to lead to new Data and Biomarkers Consortium Inventions. The following guidelines will govern any new Data or Biomarkers Consortium Inventions. As a condition of continued participation in a project, all PT Participants will adhere to the rules established in the project plan and approved by the EC for licensing Biomarkers Consortium Inventions and utilizing any Data arising from the Biomarkers Consortium project or disclosed by PT Participants as relating to the project objectives. Non-federal Participants in the PT having an ownership interest in Biomarkers Consortium Inventions will have the right to protect the Inventions, provided the Participants grant: (a) a non-exclusive, remuneration-free license for the Inventions to each of the other PT Participants and (b) a non-exclusive research license for the Inventions to others. Inventorship will be governed by U.S. law. In the case of sole Inventorship, ownership of Biomarkers Consortium Inventions will be governed by the policies of the employer of the inventor. In the case of joint Inventorship, ownership of Inventions will be governed by the policies of the employer of each inventor. For Biomarkers Consortium Inventions made under a Federal governmental grant or contract subject to the Bayh-Dole Act, FNIH will require, as a condition of PT participation, Federal grantees or contractors to voluntarily grant: (a) a nonexclusive, remuneration-free license to each of the other PT Participants and (b) a non-exclusive, remuneration-free research license to others. Agencies within the Federal government will give serious consideration to requests for licenses, on a non-exclusive basis, for Consortium Inventions owned by the Federal government in accordance with 37 C.F.R. Part 404. Participants in the PT will notify the EC before abandoning any of their patents or patent applications directed toward Biomarkers Consortium Inventions related to a biomarker or use of a biomarker or a product containing a biomarker. For non- 6
7 Federally owned or funded Inventions, Participants in the PT will permit the EC, at its option, to find a Participant of the Biomarkers Consortium or Third Party to take title (the Prosecuting Party) and pursue the patent(s) or patent application(s) at their own expense. In the event the EC finds such Prosecuting Party to take title, the PT Participant abandoning the patent or patent application shall assign the patent or patent application to the Prosecuting Party without further limitation to the right to direct and control prosecution of the application, to grant sublicenses and to enforce, provided the Prosecuting Party grants (a) a non-exclusive, remuneration-free license for the Inventions to each of the other PT Participants and (b) a non-exclusive research license for the Inventions to others. The licensing of Biomarkers Consortium Inventions shall not be restricted to PT Participants or Biomarkers Consortium members. Biomarkers Consortium Participants, grantees, and funding recipients will not be forbidden by virtue of their participation in the Biomarkers Consortium to challenge the validity or enforceability of patents or other intellectual property of other Biomarkers Consortium Participants, grantees, and contractors, including patents or Intellectual Property arising from Biomarkers Consortium-sponsored activities. Notwithstanding any of the above guidelines, neither the Biomarkers Consortium nor FNIH will have any ownership rights in Biomarkers Consortium Inventions. PT Participants will have the right to analyze Data generated in the course of the project plan within the scope of the project and data analysis plan using their own methodologies with the express condition that they will disclose methods and results arising out of their analysis to the PT within a reasonable time to be agreed upon by the PT. The status of any Inventions from such activity should be covered or considered in the project plan. VI. Participation of Funding Recipients The Biomarkers Consortium may seek to accomplish the collection, storage, analysis or other activities associated with specific Biomarkers Consortium-sponsored projects through funding agreements. Non-Federal funding agreements, in furtherance of Biomarkers Consortium projects, shall: (1) ensure that each individual involved in the project as a funding recipient will treat the project and all Data and Intellectual Property relating to the project as strictly confidential; (2) ensure that the funding recipient will have no rights or interests in Data arising from their participation in a Biomarkers Consortium project 2 ; (3) ensure that all PT Participants receive a non-exclusive, 2 In special cases where contracting parties develop tools based on their own proprietary platforms to manage or otherwise manipulate data involved in the project, such parties 7
8 remuneration-free license to any Inventions made under the funding agreement related to the project, and that others will receive a non-exclusive license for research use of such Inventions; and (4) outline the expectation that Inventions arising from Biomarkers Consortium research will either be commercialized or otherwise made available for licensing for commercial development of a product. Funding agreements entered into by Federal PT Participants will be governed by applicable Federal law, including the Bayh-Dole Act. Determinations of Exceptional Circumstance under 35 U.S.C. 202 ( DEC ) will be considered on a case-by-case basis. In the absence of a DEC, Federal Participants will request data access and intellectual property plans from applicants that address the principles of this document. may retain commercial rights to such tools provided they will grant non-exclusive research use licenses to PT Participants. 8
SPONSORED RESEARCH AGREEMENT
SPONSORED RESEARCH AGREEMENT (Collaborative Research - Jointly Owned Intellectual Property - Short Form) This Sponsored Research Agreement (the "Agreement") is made between The University of Texas, ("University"),
BOILERPLATE STTR ALLOCATION OF RIGHTS AGREEMENT PLEASE CONTACT LINDA CONCINO, UMASS LOWELL OFFICE OF RESEARCH ADMINISTRATION.
BOILERPLATE STTR ALLOCATION OF RIGHTS AGREEMENT PLEASE CONTACT LINDA CONCINO, UMASS LOWELL OFFICE OF RESEARCH ADMINISTRATION Linda_Concino@uml.edu SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) PROGRAM ALLOCATION
DATA SHARING AGREEMENT
DATA SHARING AGREEMENT This DATA SHARING AGREEMENT (this Agreement ) is effective as of, (the Effective Date ) between (the Institution ), located at and ( Study Sponsor ) located at, regarding that certain
UNIVERSITY OF WISCONSIN-STEVENS POINT OFFICE OF RESEARCH AND SPONSORED PROGRAMS
UNIVERSITY OF WISCONSIN-STEVENS POINT OFFICE OF RESEARCH AND SPONSORED PROGRAMS FINANCIAL CONFLICTS OF INTEREST POLICY FOR PUBLIC HEALTH SERVICE (PHS)-FUNDED PROJECTS The University of Wisconsin-Stevens
FINANCIAL CONFLICT OF INTEREST PLAN. November, 2013
FINANCIAL CONFLICT OF INTEREST PLAN November, 2013 CONTENTS 1.0 POLICY STATEMENT... 3 2.0 DEFINITIONS... 3 3.0 PROCEDURES... 5 3.1 RESPONSBILITIES OF DESIGNATED OFFICIAL... 5 3.2 INTERNAL REPORTING REQUIREMENTS...
RUTGERS POLICY PATENT POLICY OF RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
RUTGERS POLICY Section: 50.3.1 Section Title: Legal Matters Policy Name: Patent Policy Formerly Book: 6.4.1 Approval Authority: Board of Governors Responsible Executive: Executive Vice President for Academic
2017 Copyright The Sequoia Project. All rights reserved.
Exhibit 1 Carequality Connection Terms As used herein, Organization refers to the Carequality Connection upon which these Carequality Connection Terms are binding and Sponsoring Implementer refers to the
Standard MSKCC Agreement
CLINICAL TRIAL AGREEMENT THIS AGREEMENT (the Agreement ) is effective on the date last subscribed below (the "Effective Date"), and is by and between SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH and its
CONFLICTS OF INTEREST IN RESEARCH
IM&COI POLICY III CONFLICTS OF INTEREST IN RESEARCH (Capitalized terms are defined in the Glossary.) Presumption Against Participating in Research When Personal Financial Interests Exist If an Investigator
DATA SHARING AGREEMENT
DATA SHARING AGREEMENT Effective Date: This Data Sharing Agreement ( Agreement ) is effective as of the Effective Date between Merck KGaA, Frankfurter Strasse 250, 64271 Darmstadt, Germany ( Merck ), and
SALK INSTITUTE FOR BIOLOGICAL STUDIES PATENT AND INVENTION POLICY
SALK INSTITUTE FOR BIOLOGICAL STUDIES PATENT AND INVENTION POLICY Effective July 1, 2010 (11.03.15) 1. GENERAL POLICY AND OBJECTIVES One of the primary objectives of the Salk Institute for Biological Studies
SECTION 2. BACKGROUND
Rev. Proc. 2007-47 Table of Contents SECTION 1. PURPOSE SECTION 2. BACKGROUND SECTION 3. DEFINITIONS SECTION 4. CHANGES SECTION 5. SCOPE SECTION 6. OPERATING GUIDELINES FOR RESEARCH AGREEMENTS SECTION
Johnson & Johnson Financial Conflicts of Interest Policy
Johnson & Johnson Financial Conflicts of Interest Policy I. INTRODUCTION A. Purpose This policy implements U.S. federal requirements pertaining to Objectivity in Research promulgated by the Public Health
Standard Operating Procedures for Disclosure and Management of Financial Conflicts of Interest
Standard Operating Procedures for Disclosure and Management of Financial Conflicts of Interest Effective May 1, 2013 TABLE OF CONTENTS 1.0 GENERAL PRINCIPLES... 3 2.0 SCOPE... 3 3.0 GUIDING PRINCIPLES...
CLINICAL TRIAL AGREEMENT
PROTOCOL TITLE: PRODUCT: INSTITUTION: PRINCIPAL INVESTIGATOR: University of Connecticut Health Center CLINICAL TRIAL AGREEMENT THIS CLINICAL TRIAL AGREEMENT together with all Exhibits and Attachments,
Title: Previous Version(s): 8/01, 1/02, 6/06, 1/12, 4/12
Title: Financial Conflicts of Interest Department: Research Institute Effective Date: 3/18 Reviewed: Previous Version(s): 8/01, 1/02, 6/06, 1/12, 4/12 Policy & Procedure Replaces: Disclosure of Conflicts
UNIVERSITY - INDUSTRY SPONSORED RESEARCH AGREEMENT
UNIVERSITY - INDUSTRY SPONSORED RESEARCH AGREEMENT THIS SPONSORED RESEARCH AGREEMENT (the Agreement ), effective this day of, 20 ( Effective Date ) is made by and between Northeastern University, a non-profit
GREENVILLE HEALTH SYSTEM POLICY AND PROCEDURES Manual of Policy Directives POLICY NAME: Greenville Health System
1 THIS POLICY HAS BEEN REISSUED SINCE JULY 2004 GREENVILLE HEALTH SYSTEM POLICY AND PROCEDURES Manual of Policy Directives POLICY NAME: Greenville Health System POLICY NUMBER: S-010-17 Intellectual Property
Payment Example 2
Clinical Trial Agreements - A Moderated Discussion Health Care Compliance Association Research Compliance Conference June 3, 2015 EXAMPLES FOR DISCUSSION 1. PERSONNEL EXAMPLES Personnel Example 1 Institution
RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC. (RFMH) FINANCIAL CONFLICT OF INTEREST POLICY
RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC. (RFMH) FINANCIAL CONFLICT OF INTEREST POLICY RFMH is committed to carrying out its functions in a manner that promotes confidence in the integrity of the organization.
Policy Number: Location: Origination Date: Date of Last Review: Baylor Research Institute 8/24/2012 7/11/2012
Policy Name: Financial Conflict of Interest in Research Policy Department/Service Line: Research Subject Protection Policy Number: BHCS.BRI.SP.811.P.V12 Location: Origination Date: Date of Last Review:
TRANSLATIONAL GENOMICS RESEARCH INSTITUTE INTELLECTUAL PROPERTY POLICY 1, 2
TRANSLATIONAL GENOMICS RESEARCH INSTITUTE INTELLECTUAL PROPERTY POLICY 1, 2 1. BACKGROUND MISSION STATEMENT: This Intellectual Property Policy ( Policy ) is intended to set forth concisely the basic objectives
POLICY NO.: BHSF POLICY TITLE: Individual Financial Conflicts of Interest (FCOI) in Research
A dm inis trative Departmental POLICY TITLE: Individual Financial Conflicts of Interest (FCOI) in Research SUMMARY & PURPOSE: The purpose of this policy and procedure is to promote objectivity in research
Johns Hopkins University. Policy on Individual Financial Interests and Financial Conflict of Interests 1, 2 in Research
Johns Hopkins University Policy on Individual Financial Interests and Financial Conflict of Interests 1, 2 in Research This policy applies to the Bloomberg School of Public Health, Krieger School of Arts
Government Owned, Government Operated (GOGO) Laboratories
Government Owned, Government Operated (GOGO) Laboratories Mojdeh Bahar, J.D., M.A., CLP The National Institutes of Health Nashville, Tennessee May 2, 2011 2 Mojdeh Bahar FLC Mid-Atlantic Regional Coordinator
University of New England Investigator Significant Financial Interest Disclosure Policy for Sponsored Projects Originally Adopted March 2005
University of New England Investigator Significant Financial Interest Disclosure Policy for Sponsored Projects Originally Adopted March 2005 Revised August 2012 Table of Contents Introduction... 3 Background...
Approver: Dr. Robert Steiner Executive Director, Marshfield Clinic Research Foundation
Policy # 1024.1(previous number) Policy Title: Effective Date: mm/dd/yyyy Supersedes: N/A Approver: Dr. Douglas Reding Vice President, Marshfield Clinic Date Approver: Dr. Robert Steiner Executive Director,
UNIVERSITY LICENSING GUIDELINES (revised October 1, 2001)
'.. UNIVERSITY LICENSING GUIDELINES revised October 1, 2001) The purpose of licensing University inventions is to provide a mechanism to encourage the practical application of the results of University
Objectivity in Research and Investigator Financial Disclosure
Objectivity in Research and Investigator Financial Disclosure Scope This policy applies to Mount Mary University employees who serve as investigators and who apply for funding through Mount Mary University
Auburn University Procedures for Public Health Service Financial Conflicts of Interest Regulations
1 Auburn University Procedures for Public Health Service Financial Conflicts of Interest Regulations Introduction The Public Health Service (PHS) has issued its final rule entitled Responsibility of Applicants
REGENERON PHARMACEUTICALS, INC. FINANCIAL CONFLICTS OF INTEREST POLICY FOR PHS-FUNDED RESEARCH
REGENERON PHARMACEUTICALS, INC. FINANCIAL CONFLICTS OF INTEREST POLICY FOR PHS-FUNDED RESEARCH I. INTRODUCTION This Financial Conflicts of Interest Policy for PHS-Funded Research ( FCOI Policy ) implements
MAIMONIDES MEDICAL CENTER SUBJECT: CONFLICTS OF INTEREST IN HUMAN RESEARCH & PHS FUNDED RESEARCH
MAIMONIDES MEDICAL CENTER CODE: RES-021 (Reissued) ORIGINALLY ISSUED: October 22, 2009 SUBJECT: CONFLICTS OF INTEREST IN HUMAN RESEARCH & PHS FUNDED RESEARCH I. POLICY Consistent with current law and to
ARTICLE I (Scope of Collaboration)
MEMORANDUM OF UNDERSTANDING BETWEEN THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, ON BEHALF OF ITS DAVIS CAMPUS One Shields Avenue Davis, CA 95616 UNITED STATES OF AMERICA AND [RESEARCH INSTITUTION] [CITY/COUNTRY]
Office of Research Administration
Revision: 8/10/2016 Effective Date: 8/24/2012 Office of Research Research Policy and Operational Guidance: Financial Conflicts of Interest (FCOI) in PHS-Funded Research and Research Training Oakland University
MODEL POLICY [INSERT NAME OF YOUR ORGANIZATION] CONFLICT OF INTEREST POLICY APPLICABLE TO A SUBAWARD ISSUED UNDER A PUBLIC HEALTH SERVICES PRIME AWARD
MODEL POLICY [INSERT NAME OF YOUR ORGANIZATION] CONFLICT OF INTEREST POLICY APPLICABLE TO A SUBAWARD ISSUED UNDER A PUBLIC HEALTH SERVICES PRIME AWARD The federal Public Health Service (PHS) has adopted
FEDERAL RESEARCH. DOE Is Addressing Invention Disclosure and Other Challenges but Needs a Plan to Guide Data Management Improvements
United States Government Accountability Office Report to Congressional Requesters January 2015 FEDERAL RESEARCH DOE Is Addressing Invention Disclosure and Other Challenges but Needs a Plan to Guide Data
PART TWO, CHAPTER XII INTELLECTUAL PROPERTY
PART TWO, CHAPTER XII INTELLECTUAL PROPERTY Sec. 1. Philosophy and Objectives It is the objective of the Board to provide an intellectual property policy that will encourage the development of inventions
Industry Sponsored Research Agreement
Industry Sponsored Research Agreement An overview of the terms and conditions Sponsored Research Agreements A Sponsored Research Agreement (SRA) is a contract between the University and a sponsor for the
Clemson University Financial Conflict of Interest Policy for PHS/NIH Supported Research
Clemson University Financial Conflict of Interest Policy for PHS/NIH Supported Research Persons covered by this policy This policy applies to all faculty and staff, including all full-time, part-time,
BY ELECTRONIC MAIL TO
BY ELECTRONIC MAIL TO NONPROFITIPREGS@CIRM.CA.GOV Mr. C. Scott Tocher Interim Counsel California Institute for Regenerative Medicine 250 King Street San Francisco, CA 94107 Comments to Proposed Changes
IBM Watson Care Manager Cloud Service
Service Description IBM Watson Care Manager Cloud Service This Service Description describes the Cloud Service IBM provides to Client. Client means the company and its Authorized Users and recipients of
Licensing Issues in the Life Sciences Industry: Negotiating University License Agreements
Licensing Issues in the Life Sciences Industry: Negotiating University License Agreements Monday, March 5, 2018 Scott J. Catlin, Associate Vice President for Technology Ventures at UR Ventures - University
Intellectual Property Policy
Intellectual Property Policy For Partners-Affiliated Hospitals and Institutions The Hospitals and other Institutions affiliated with Partners HealthCare System are not-for-profit corporations which share
Conflict of Interest Policy for Research Investigators
Conflict of Interest Policy for Research Investigators OVPR Effective 24 August 2012 1 Conflict of Interest Policy for Research Investigators The University is responsible for maintaining objectivity in
IN ORDER TO STREAMLINE THE REVIEW PROCESS AND TO PREVENT DELAY PLEASE MAKE SURE ALL FIELDS ARE COMPLETED, SIGN AND DATE.
Invention Disclosure Form IN ORDER TO STREAMLINE THE REVIEW PROCESS AND TO PREVENT DELAY PLEASE MAKE SURE ALL FIELDS ARE COMPLETED, SIGN AND DATE. SUBMIT YOUR LIFESPAN DISCLOSURE DIRECTLY TO PEGGY MCGILL,
SILENT SPRING INSTITUTE POLICY AND PROCEDURES ON FINANCIAL CONFLICTS OF INTEREST IN PUBLIC HEALTH SERVICE FUNDED RESEARCH
SILENT SPRING INSTITUTE POLICY AND PROCEDURES ON FINANCIAL CONFLICTS OF INTEREST IN PUBLIC HEALTH SERVICE FUNDED RESEARCH This policy implements the requirements of certain federal regulations, specifically
CLINICAL STUDY AGREEMENT
CLINICAL STUDY AGREEMENT This CLINICAL STUDY AGREEMENT ( Agreement ) is made effective as of the [number] day of [month], [year] (the Effective Date ), and is by and among Recitals (1) ASTRAZENECA [PHARMACEUTICALS]
To: Vice Chancellors, Deans, Administrative Staff, Department Heads, and Students.
Chancellor s Memorandum CM-35 Conflicts of Interest in Research: Managing Potential Financial and Non-Financial Conflicts of Interest of Individuals and the Institution To: Vice Chancellors, Deans, Administrative
TEMPLE UNIVERSITY BOARD OF TRUSTEES POLICIES AND PROCEDURES MANUAL
TEMPLE UNIVERSITY BOARD OF TRUSTEES POLICIES AND PROCEDURES MANUAL Title: Financial Conflict of Interests in Research Policy Number: 02.52.12 Issuing Authority: President Responsible Officer: Senior Vice
OBJECTIVITY IN RESEARCH POLICY
OBJECTIVITY IN RESEARCH POLICY This Policy addresses NCQA s responsibility for ensuring objectivity in research in accordance with 42 CFR Part 50, Subpart F Promoting Objectivity in Research, and 45 CFR
Firms currently approved under the 2011 RFP must submit a new proposal in order to be considered for selection.
DEADLINE FOR SUBMISSION EXTENDED UNTIL AUGUST 8, 2014 UNIVERSITY OF NORTH CAROLINA INTELLECTUAL PROPERTY COUNSEL SERVICES REQUEST FOR PROPOSALS May 14, 2014 1. PURPOSE The University of North Carolina
TITLE: Conflict of Interest, Research
PAGE 1 of 8 TITLE: Conflict of Interest, Research IDENTIFIER: S-FW-LD-0004 APPROVED: Executive Cabinet 12/11/12 ORIGINAL FORMULATION: 12/08 REVISED: 12/12 REVIEWED: 06/12 EFFECTIVE: Acute Care: ENC: 12/17/12
Patent and Copyright Policies
Patent and Copyright Policies I. Policy The University of North Carolina is dedicated to instruction, research, and extending knowledge to the public (public service). It is the policy of the University
ADDENDUM TO THE BROKER AGREEMENT BETWEEN COMMON GROUND HEALTHCARE COOPERATIVE AND BROKER
ADDENDUM TO THE BROKER AGREEMENT BETWEEN COMMON GROUND HEALTHCARE COOPERATIVE AND BROKER This Addendum ( Addendum ) to the Broker Agreement ( Agreement ) by and between [INSERT BROKER LEGAL ENTITY] ( Broker
Policy Number: Policy Name: Intellectual Property Policy
Page 1 6-908 Intellectual Property Policy The Arizona Board of Regents and the three universities that the board governs, are all dedicated to teaching, research, and the extension of knowledge to the
INTRODUCTION. MISSION - University of Tennessee Research Foundation
STATEWIDE TRAINING Mary Ann Russell University of Tennessee Research Foundation 1534 White Ave., Suite 403 Knoxville, TN 37996-1527 865.974.1834 marussell@utk.edu INTRODUCTION MISSION - University of Tennessee
Project ECHO (Extension for Community Healthcare Outcomes)
Project ECHO (Extension for Community Healthcare Outcomes) PROJECT ECHO INTELLECTUAL PROPERTY TERMS OF USE AGREEMENT Effective ( DATE ), The Regents of the University of New Mexico, for its public operation
APPENDIX D. PATENT AND COPYRIGHT POLICY The Texas State University System
158 APPENDIX D. PATENT AND COPYRIGHT POLICY The Texas State University System 1. COPYRIGHT POLICY. 1.1 PURPOSE AND SCOPE. The purpose of The Texas State University System copyright policy is to outline
FINANCIAL DISCLOSURES AND CONFLICTS OF INTEREST IN CLINICAL RESEARCH
FINANCIAL DISCLOSURES AND CONFLICTS OF INTEREST IN CLINICAL RESEARCH Richard S Liner, JD Ronald H. Clark, PhD, JD Arent Fox Kintner Plotkin & Kahn, PLLC Washington D.C./New York 1 In light of the expansion
UNI Office of Research and Sponsored Programs Policy on Conflicts of Interest Involving Research Funded by the Public Health Service
UNI Office of Research and Sponsored Programs Policy on Conflicts of Interest Involving Research Funded by the Public Health Service 8-22-12 Purpose of Policy The purpose of this policy is to ensure that
Water Utility Disinfection Survey
6666 West Quincy Avenue Denver, CO 80235-3098 T 303.794.7711 www.awwa.org American Water Works Association Request for Proposal Water Utility Disinfection Survey Issued by: Technical and Education Council
IBM Phytel Cloud Services
Service Description IBM Phytel Cloud Services This Service Description describes the Cloud Service IBM provides to Client. Client means the company and its authorized users and recipients of the Cloud
John Kearny, Janice Nicholson, Patricia Notarangelo, Rebbie Pamintuan, Nadia Taylor. Additional Editors: Gwen Burrows Additional Readers:
Issuing Department: Research Institute Category: Research Institute Issuing Authority: Janet Rossant Subcategory: Hospital-wide Policies Section Name: Research Operations Publication Status: Final Content
INTERNATION CENTER FOR RESEARCH ON WOMEN (ICRW) PHS FUNDED RESEARCH FINANCIAL CONFLICT OF INTEREST (FCOI) POLICY
INTERNATION CENTER FOR RESEARCH ON WOMEN (ICRW) PHS FUNDED RESEARCH FINANCIAL CONFLICT OF INTEREST (FCOI) POLICY A. INTRODUCTION The U.S. Department of Health and Human Services (HHS) issued a final rule
1. Disclosure of Significant Financial Interest means an Investigator s disclosure of significant financial interests to Monmouth University.
FINANCIAL CONFLICT OF INTEREST AND OBJECTIVITY IN RESEARCH I. PURPOSE Monmouth University believes that it is vital to maintain objectivity in research and that all research must be conducted with the
UNIVERSITY OF NEVADA, LAS VEGAS Master Agreement Agreement No. Task Order and this Agreement, the terms of this Agreement shall govern.
UNIVERSITY OF NEVADA, LAS VEGAS Master Agreement Agreement No. This agreement is made effective as of Date (Effective Date), by and between the Board of Regents, Nevada System of Higher Education on behalf
Financial Conflict of Interest for Externally Funded Research Reporting Process (July 1, 2017)
Financial Conflict of Interest for Externally Funded Research Reporting Process (July 1, 2017) Introduction This process governing financial conflicts of interest (FCOI) applies to all Centenary Investigators
Florida Hospital Office of Research Integrity 901 N Lake Destiny Drive, Suite 400 Maitland, FL , ext
Florida Hospital posts Policies and Standard Operating Procedures on a Controlled Document site. The attached is a true copy of the current Florida Hospital Policy and Procedure (P&P) and for Financial
VNSNY CORPORATE POLICY AND PROCEDURE
VNSNY CORPORATE POLICY AND PROCEDURE TITLE: APPLIES TO: PUBLIC HEALTH SERVICE (PHS) FINANCIAL CONFLICT OF INTEREST (FCOI) POLICY All VNSNY Entities, but only to VNSNY personnel who are Investigators on
Accelerated Clinical Trial Agreement
Accelerated Clinical Trial Agreement This Accelerated Clinical Trial (ACTA) Agreement ( Agreement ) is made as of this {DAY} day of {MONTH}, {YEAR} (the Effective Date ) by and between {INSTITUTION NAME},
Dear Colleague, In the steadfast pursuit of excellence, I remain, Sincerely yours,
Dear Colleague, Every employee, manager and physician plays a vital role in realizing Lifespan s mission: Delivering health with care. Essential to achieving this mission is Lifespan s continuous commitment
Kyushu University: Rules on the Handling of Intellectual Property
Kyushu University: Rules on the Handling of Intellectual Property Chapter 1: General Provisions Section 1: Purpose These Kyushu University (the University ) Rules on the Handling of Intellectual Property
Capella Education Company Code of Business Conduct COMPLIANCE WITH LAWS AND ETHICAL STANDARDS
Capella Education Company Code of Business Conduct COMPLIANCE WITH LAWS AND ETHICAL STANDARDS Capella Education Company and its subsidiaries (collectively, Capella ) conduct their business in strict compliance
AMERICAN CANCER SOCIETY, INC. FINANCIAL CONFLICT OF INTEREST POLICY FOR PROMOTING OBJECTIVITY IN RESEARCH
AMERICAN CANCER SOCIETY, INC. FINANCIAL CONFLICT OF INTEREST POLICY FOR PROMOTING OBJECTIVITY IN RESEARCH Introduction The American Cancer Society, Inc. ( ACS ) seeks excellence in the discovery and dissemination
American Thoracic Society International Conference SUMMARY AND DEFINITIONS OF ATS POLICIES ON CONFLICT OF INTEREST AND TOBACCO INDUSTRY RELATIONSHIPS
Please note: this document is intended as an optional resource for Conference organizers, chairs and presenters, as a summary of information made available on the ATS COI Website and ATS Website. If you
MSSNG A Program of Autism Speaks Inc. 85 Devonshire St Boston, MA 02109, USA (617) MSSNG DATABASE ACCESS AGREEMENT (DAA) (VERSION 1.
MSSNG A Program of Autism Speaks Inc. 85 Devonshire St Boston, MA 02109, USA (617) 726-1515 MSSNG DATABASE ACCESS AGREEMENT (DAA) (VERSION 1.6) INTRODUCTION MSSNG is a groundbreaking program sponsored
CDISC Intellectual Property Policy
CDISC Intellectual Property Policy Revision History Date Revision Description Author 16 July 2004 0.1 Original draft MS Legal Counsel and Independent 21 Sept 2004 0.2 CDISC-specific draft, following Rebecca
FSB REVISION OF THE INTELLECTUAL PROPERTY POLICY AND PATENT POLICY. Date of First Reading: Date of Second Reading: Tanja Steigner, Chair
Date Passed Senate: 12-4-12 Date of ESU President's Approval: 12-7-12 FSB 12005 REVISION OF THE INTELLECTUAL PROPERTY POLICY AND PATENT POLICY Date of First Reading: Date of Second Reading: Senate Sponsor:
A Basic Introduction to Intellectual Property Rights. Pursuant to NASA Procurement Contracts
National Aeronautics and Space Administration A Basic Introduction to Intellectual Property Rights Pursuant to NASA Procurement Contracts 2017 Ted Ro Deputy Chief Counsel/Intellectual Property Attorney
Effective Date August 1, Date of Last Review September 2016 Date of Next Review September Date of Adoption October 2003.
Minnesota State University, Mankato University Policies Policy Name: Conflict of Financial Interest with Grants and Sponsored Programs Custodian of Policy: Provost and Vice President for Academic Affairs
CONFLICT OF INTEREST: ACCP PUBLICATIONS POLICY AND PROCEDURE
CONFLICT OF INTEREST: ACCP PUBLICATIONS POLICY AND PROCEDURE Background In August 1999, the ACCP Board of Regents approved the policy, Conflict of Interest: ACCP Publications Policy and Procedure. At its
Partners In Health Financial Conflicts of Interest Policy
Partners In Health Financial Conflicts of Interest Policy In accordance with the requirements set forth by the Public Health Service (PHS),, Partners In Health (PIH) has established a Financial Conflict
INTELLECTUAL PROPERTY POLICY
INTELLECTUAL PROPERTY POLICY Introduction The Rockefeller University ( University ) recognizes that inventions may be made and copyrightable works may be created in the course of research supported by
Financial Conflict of Interest Policy and Procedural Manual
Financial Conflict of Interest Policy and Procedural Manual Financial Conflict of Interest... 1 Policy and Procedural Manual... 1 Financial Conflict of Interest Policy... 2 Disclosure of Financial Conflicts
1. General Provisions.
1. General Provisions. NCSU Standard Terms and Conditions A. These terms and conditions apply to all Fixed Price Subawards issued by NCSU. They are binding when incorporated by reference into a fully executed
NYU LANGONE POLICY ON CONFLICTS OF INTEREST IN BUSINESS AFFAIRS. Issue Date: April 1, 2009 Reissue Date: June 29, Contents: I.
NYU LANGONE POLICY ON CONFLICTS OF INTEREST IN BUSINESS AFFAIRS Issue Date: April 1, 2009 Reissue Date: June 29, 2016 Contents: I. Applicability II. General Policy III. Procedures for Disclosure IV. Review
Central Office of Research Administration
SECTION: PURPOSE STATEMENT To set forth the process for reviewing financial interests, and for identifying and addressing financial conflicts of interest ( FCOI ) in Research (as defined later in this
MASTER CLINICAL TRIAL AGREEMENT
MASTER CLINICAL TRIAL AGREEMENT THIS MASTER CLINICAL TRIAL AGREEMENT ( Agreement ), is effective as of the latest date that a Party hereto signs this Agreement (the Effective Date ), by and between ALLERGAN
DATA SHARING AGREEMENT. Between LEO Pharma A/S and [insert name of Researcher]
DATA SHARING AGREEMENT Between LEO Pharma A/S and [insert name of Researcher] This Data Sharing Agreement ( Agreement ) effective as of the date of the last signature (the Effective Date ) is entered into
Referral Agreement. 2.7 Under Xennsoft s direction, assist in the setup, training and support of the Products with
Referral Agreement This Referral Agreement ( Agreement ) grants to the person or entity Referring Party identified below ( Contractor ) the right to refer to Xennsoft LLC, a Utah Limited Liability Company
AMERICAN HEALTH LAWYERS ASSOCIATION Tax Issues for Healthcare Organizations October 15-16, 2012
AMERICAN HEALTH LAWYERS ASSOCIATION Tax Issues for Healthcare Organizations October 15-16, 2012 Elements of a Post-Issuance Tax Compliance Program for Tax-Exempt Bonds Edwin G. Oswald, Esq. Orrick, Herrington
PRACTICE TRANSFORMATION NETWORK PROGRAM PARTICIPATION AGREEMENT
PRACTICE TRANSFORMATION NETWORK PROGRAM PARTICIPATION AGREEMENT THIS PROGRAM PARTICIPATION AGREEMENT ( Agreement ) is made and entered into as of the dates provided herein below, and effective as of the
Financial Conflict of Interest (FCOI) Training for Investigators
The primary objective of conflict of interest review is to protect the integrity of research. Financial interests with entities outside the USF System are not inherently unethical, illegal or wrong. However,
State of [INSERT STATE] County of [INSERT COUNTY] Facilities Use Agreement Between [INSERT COMPANY NAME] and [INSERT UNIVERSITY] for access to
State of [INSERT STATE] County of [INSERT COUNTY] Facilities Use Agreement Between [INSERT COMPANY NAME] and [INSERT UNIVERSITY] for access to [INSERT BUILDING AND ROOM NUMBER] THIS FACTILITIES USE AGREEMENT
November 2, Dear AIPPI National Groups:
November 2, 2011 Dear AIPPI National Groups: As many of you are aware, the United States Congress passed the America Invents Act ( AIA ) into law on September 16, 2011. The America Invents Act includes
Partner Code of Conduct and Business Ethics
Oracle PartnerNetwork Partner Code of Conduct and Business Ethics V040709 1 I. APPLICABILITY This Code is applicable to you as an Oracle Partner, your resellers, and to all personnel employed by or engaged
Statement of Policy in Regard to Intellectual Property
Statement of Policy in Regard to Intellectual Property Adopted by the President and Fellows of Harvard College on November 3, 1975 as the Statement of Policy in Regard to Inventions, Patents, and Copyrights
CAROLINA EXPRESS USER GUIDE
CAROLINA EXPRESS USER GUIDE Introduction 2 Carolina Express Approval Business Plan Review Procedures 3 Carolina Express Operations Management and Communications 5 Patent Prosecution Procedures 6 References
Committee Approval(s) Standards Committee 06/19/13. Current Content Expert: Megan Bailey, Manager, Office of Research Compliance
Policy Procedure Originator: Office of Research Compliance Current Content Expert: Megan Bailey, Manager, Office of Research Compliance Department Head: Brent Dethlefs, Director of Research Institute Executive
Jarvis Christian College Intellectual Property Policy
Jarvis Christian College Intellectual Property Policy Jarvis Christian College hereby establishes this Intellectual Property ( IP ) Policy with respect to the development, protection, and transfer of rights